96. Crohn disease
2,209 clinical trials, 1,276 drugs (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002857-29-HU (EUCTR) | 04/01/2006 | 18/08/2005 | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease | Moderate to severe, active Crohn’s disease MedDRA version: 3.2;Level: LLT;Classification code 10011401 | Product Name: STA-5326 mesylate Product Code: S38 Other descriptive name: STA-6838, STA-5326 m, S38 | Synta Pharmaceutical Corporation | NULL | Not Recruiting | Female: yes Male: yes | 282 | Hungary | |||
| 2 | NCT00250198 (ClinicalTrials.gov) | November 3, 2005 | 5/11/2005 | The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease | A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease | Crohn's Disease | Drug: STA-5326 | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | 75 Years | All | 12 | Phase 2 | United States |
| 3 | NCT00234741 (ClinicalTrials.gov) | November 2005 | 5/10/2005 | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease | A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease | Crohn's Disease | Drug: STA-5326 mesylate | Synta Pharmaceuticals Corp. | National Institute of Allergy and Infectious Diseases (NIAID);National Institutes of Health (NIH) | Completed | 18 Years | 75 Years | Both | 12 | Phase 2 | United States |
| 4 | NCT00138840 (ClinicalTrials.gov) | August 2005 | 26/8/2005 | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease | A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease | Crohn's Disease | Drug: STA-5326 mesylate | Synta Pharmaceuticals Corp. | NULL | Completed | 18 Years | 75 Years | Both | 282 | Phase 2 | United States;Canada |
| 5 | NCT00088062 (ClinicalTrials.gov) | February 2004 | 19/7/2004 | STA-5326 in Crohn's Disease Patients | A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450 | Crohn's Disease | Drug: STA-5326 | Synta Pharmaceuticals Corp. | NULL | Completed | 18 Years | 65 Years | Both | 48 | Phase 1;Phase 2 | United States |